Rybrevant Faspro Wins FDA Nod in Advanced Head and Neck Cancer
FDA grants accelerated approval to subcutaneous amivantamab for recurrent or metastatic HNSCC after a 42% response rate in OrigAMI-4. Eligibility, data, safety and next steps.
Tag: amivantamab
Read More